ProBioGen, a Berlin, Germany-based development and manufacturing specialist, and Immunogenesis, a spin-off of the MD Anderson Cancer Center, announced on March 24, 2020 that they have signed a service agreement for cell-line development, process development, and GMP manufacturing at 1000-L bioreactor scale for Immunogenesis’ lead immuno-oncology candidate, a monoclonal antibody (mAb).
According to a ProBioGen press release, ProBioGen will facilitate the development and of the mAb candidate at its new facility in Berlin.
